Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19
Status:
Terminated
Trial end date:
2020-11-18
Target enrollment:
Participant gender:
Summary
Study D822FC00005 will investigate the Phamacokinetics, Safety and tolerability of
Acalabrutinib suspension when delivered via a nasogastric tube and co-administered with a
Proton Pump Inhibitor, in the treatment of COVID-19.